Wegovy is covered by some insurance plans, but coverage varies dramatically depending on whether you have employer-sponsored insurance, Medicare, or Medicaid. Only about 1 in 5 large employers currently cover GLP-1 medications for weight loss, and most state Medicaid programs still exclude them. The good news: coverage is expanding quickly, and there are several ways to reduce your costs even without full insurance coverage.
Employer-Sponsored Insurance
If you get health insurance through your job, coverage depends largely on the size of your employer. According to a 2025 KFF employer survey, 19% of firms with 200 or more workers cover GLP-1 drugs like Wegovy for weight loss. The breakdown by company size tells the real story:
- 200 to 999 employees: 16% cover Wegovy for weight loss
- 1,000 to 4,999 employees: 30% cover it
- 5,000+ employees: 43% cover it
The trend is moving in the right direction. Among the largest employers, coverage jumped from 28% in 2024 to 43% in 2025. Still, the majority of workers at small and mid-size companies don’t have coverage for weight loss medications specifically.
Even when your plan does cover Wegovy, you’ll almost certainly need prior authorization. That means your doctor has to submit documentation to your insurer proving the prescription is medically necessary before the pharmacy will fill it. Insurers typically want to see a BMI of 30 or higher (or 27 with a weight-related condition like high cholesterol or high blood pressure), plus evidence that you’ve tried diet and exercise without adequate results.
Medicare Coverage
Medicare has historically been prohibited from covering weight loss drugs. That changed partially in 2024 when the FDA approved Wegovy for a second use: reducing cardiovascular risk in people with established heart disease who also have obesity or overweight. Because this indication isn’t classified as a weight loss drug, Medicare Part D plans are now permitted to add Wegovy to their formularies.
The catch is that this coverage is narrow. You need to have established cardiovascular disease, defined as a prior heart attack, prior stroke, or peripheral arterial disease, along with obesity or overweight. If you’re on Medicare and want Wegovy purely for weight management without that cardiovascular history, Part D plans still cannot cover it. Individual Part D plans also have discretion over whether to include Wegovy on their formulary at all, so coverage isn’t guaranteed even if you meet the criteria.
Medicaid Coverage
Medicaid coverage for Wegovy remains the most limited. As of January 2026, only 13 state Medicaid programs cover GLP-1 medications for obesity treatment. States are not required to cover weight loss drugs under Medicaid, so this remains optional.
The landscape has actually gotten worse in some states. Four states, including California, Pennsylvania, New Hampshire, and South Carolina, recently eliminated their Medicaid coverage for obesity-related GLP-1 prescriptions due to cost concerns. North Carolina briefly dropped coverage during a budget dispute but reinstated it in late 2025.
There are two exceptions where Medicaid must cover these drugs regardless of state policy. If Wegovy is prescribed for an FDA-approved use other than obesity (such as cardiovascular risk reduction or, for Zepbound, obstructive sleep apnea), states are required to cover it. Coverage is also required for children when deemed medically necessary under Medicaid’s screening and treatment benefit.
How to Check Your Specific Plan
The fastest way to find out if your plan covers Wegovy is to look up your plan’s formulary, which is the list of medications your insurer will pay for. You can usually find this by logging into your insurance portal or calling the member services number on the back of your card. Search for “semaglutide” or “Wegovy” specifically, and pay attention to which tier it falls under, since higher tiers mean higher copays.
Even if Wegovy appears on your formulary, expect a prior authorization requirement. Your doctor’s office will handle the submission, but you can speed things along by having documentation ready: your BMI history, any weight-related conditions you’ve been diagnosed with, and a record of previous weight loss attempts. Some plans also require that you’ve tried and failed other treatments first.
What to Do If You’re Denied
A denial isn’t necessarily the final answer. Insurance appeals for Wegovy do succeed, particularly when the medical necessity case is strong. In one New York state case, a denial was overturned after the patient documented that she had tried diet and exercise for 12 months without success, had obesity-related conditions including liver cysts and high cholesterol, and had tried all formulary alternatives.
If your claim is denied, ask your insurer for the specific reason in writing. Common reasons include not meeting BMI requirements, insufficient documentation of prior weight loss attempts, or the drug not being on your plan’s formulary. Your doctor can submit a letter of medical necessity as part of a formal appeal, citing the FDA approval and peer-reviewed evidence for semaglutide in obesity treatment. Most states require insurers to process appeals within 30 to 60 days.
Costs With and Without Coverage
If your commercial insurance covers Wegovy, a manufacturer savings card from Novo Nordisk can bring your copay down to as little as $25 per month, with up to $100 in savings per monthly fill. This card is available to people with commercial insurance that covers the drug, but it excludes anyone on Medicare, Medicaid, TRICARE, VA benefits, or other government programs. It also won’t work if your insurer uses an accumulator adjustment or copay maximizer program, which some plans have implemented to prevent manufacturer coupons from counting toward your deductible.
If you don’t have insurance coverage at all, Novo Nordisk offers self-pay pricing through its NovoCare pharmacy. New patients pay $199 per month for the two lowest doses (0.25 mg and 0.5 mg) for their first two fills, then $349 per month for injectable doses and $149 per month for the oral pill formulation. The higher-dose injectable pen (7.2 mg) runs $399 per month at self-pay pricing. These prices are significantly lower than the full list price and are available for pharmacy pickup or home delivery.
Federal employees and people on Affordable Care Act marketplace plans are eligible for the manufacturer savings card, since those are not classified as government programs for the purposes of the offer. State employee plans also qualify.
Why Coverage Is So Uneven
The core issue is cost. GLP-1 medications are among the most expensive drug categories insurers have ever faced, and the potential patient population is enormous. Roughly 40% of American adults have obesity, which means covering these drugs could represent a massive new expense for any plan. Employers and state Medicaid programs are weighing the long-term health savings of treating obesity against the immediate budget impact, and many are still landing on the side of exclusion. As prices come down through competition and as more FDA-approved uses expand required coverage categories, the insurance landscape is likely to keep shifting toward broader access.